Related Posts
FDA May Move Digital Breast Tomosynthesis From PMA to 510(k)
FDA has proposed reclassifying digital breast tomosynthesis (DBT) systems from Class III to Class II. If finalized, the change would replace the current PMA framework for these systems with Class II special controls plus 510(k) premarket notification requirements. For manufacturers, this could materially change both new-product submissions and lifecycle-management strategy.…
FDA QMSR 2026: Implementation guide for manufacturers
Learn new requirements of FDA QMSR implementation: How to align with ISO 13485, bridge gaps in records/labeling, prepare for risk-based inspections, and avoid shutdown risks.
Regulation Roadblocks Cloud AI Integration in Real‑World Evidence
Learn how AI integration in real-world evidence demands high-quality data, robust governance, and regulatory compliance to ensure trustworthy, regulator-ready insights.